Startseite UR

Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial

Weller, Johannes ; Tzaridis, Theophilos ; Mack, Frederic ; Steinbach, Joachim Peter ; Schlegel, Uwe ; Hau, Peter ; Krex, Dietmar ; Grauer, Oliver ; Goldbrunner, Roland ; Bähr, Oliver ; Uhl, Martin ; Seidel, Clemens ; Tabatabai, Ghazaleh ; Brehmer, Stefanie ; Bullinger, Lars ; Galldiks, Norbert ; Schaub, Christina ; Kebir, Sied ; Stummer, Walter ; Simon, Matthias ; Fimmers, Rolf ; Coch, Christoph ; Glas, Martin ; Herrlinger, Ulrich ; Schäfer, Niklas



Zusammenfassung

Background The CeTeG/NOA-09 trial showed significantly longer overall survival with combined lomustine- temozolomide therapy compared with standard temozolomide for patients with glioblastoma with methylated MGMT promoter. The trial also aimed to investigate the effect of lomustine-temozolomide therapy on health-related quality of life (HRQOL) and neurocognitive function, which we report here. ...

plus


Nur für Besitzer und Autoren: Kontrollseite des Eintrags
  1. Universität

Universitätsbibliothek

Publikationsserver

Kontakt:

Publizieren: oa@ur.de
0941 943 -4239 oder -69394

Dissertationen: dissertationen@ur.de
0941 943 -3904

Forschungsdaten: datahub@ur.de
0941 943 -5707

Ansprechpartner